Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADALAT vs CALAN SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Essential hypertension,Chronic stable angina,Variant (Prinzmetal) angina,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT),Off-label: migraine prophylaxis, cluster headache,Off-label: hypertrophic cardiomyopathy
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Oral: 180–240 mg once daily; maximum 480 mg/day.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Terminal elimination half-life is 6-12 hours (average ~8 hours) after single oral dose; may increase to 12-16 hours with chronic dosing due to saturable hepatic metabolism; clinical context: requires dosing adjustments in hepatic impairment.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Primarily hepatic via CYP3A4; first-pass metabolism; major metabolite norverapamil retains 20% activity.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Approximately 70% of the dose is excreted as metabolites in the urine; 3-4% as unchanged drug; 25% eliminated in feces via biliary excretion.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
Approximately 90% bound to plasma proteins (mainly albumin).
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
3.5 L/kg; indicates extensive tissue binding and distribution beyond plasma volume.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
Oral (sustained-release): 40-60% due to first-pass metabolism; immediate-release: 70-80% when fasting but reduced to ~50% with food.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Cr Cl <30 m L/min: reduce dose by 50–75% of normal; initiate at lower end of dosing range.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Child-Pugh A: no adjustment; Child-Pugh B or C: reduce dose by 50% and monitor.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Not FDA-approved for children; limited data: 4–8 mg/kg/day divided twice daily (immediate-release form only).
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
Initiate at 120 mg once daily; titrate slowly due to increased bioavailability and prolonged half-life.
None
None
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Heart failure: may exacerbate due to negative inotropic effects,Hypotension,Bradycardia/AV block: avoid in sick sinus syndrome or high-grade AV block without pacemaker,Hepatic impairment: reduce dose,Concomitant beta-blockers: increased risk of bradycardia and heart failure,Digoxin toxicity: verapamil increases digoxin levels
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Severe left ventricular dysfunction (ejection fraction <30%),Cardiogenic shock,Sick sinus syndrome or 2nd/3rd degree AV block (except with functioning pacemaker),Atrial fibrillation/flutter with accessory bypass tract (e.g., WPW),Hypersensitivity to verapamil
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Avoid grapefruit and grapefruit juice as they can increase verapamil levels. Limit alcohol consumption as it may enhance hypotensive effects. High-fat meals may delay absorption but not significantly affect overall bioavailability.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Verapamil (CALAN SR) is classified as FDA Pregnancy Category C. First trimester: Animal studies have shown embryotoxicity and fetotoxicity, but no well-controlled human studies exist. Risk cannot be ruled out. Second/third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion. Avoid use in pregnancy unless benefit outweighs risk.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
Verapamil is excreted into breast milk with a milk-to-plasma ratio (M/P) of approximately 0.23 to 0.94 (mean~0.6). Infant dose is low (<5% maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Consider monitoring infant for bradycardia, hypotension, and constipation.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
Pregnancy may increase verapamil clearance due to expanded plasma volume and enhanced renal/hepatic metabolism. Dose adjustments may be needed to maintain therapeutic effect; monitor clinical response and consider therapeutic drug monitoring. Start at lower doses and titrate cautiously.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
CALAN SR (verapamil sustained-release) is a non-dihydropyridine calcium channel blocker used for hypertension and angina. Avoid use in patients with pre-existing severe left ventricular dysfunction, hypotension, or sick sinus syndrome without a pacemaker. Caution with concomitant beta-blockers due to risk of bradycardia or heart block. Verapamil is a potent CYP3A4 inhibitor; monitor for increased levels of statins, cyclosporine, and other CYP3A4 substrates.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
Take exactly as prescribed; do not crush or chew the extended-release tablet.,Can be taken with or without food, but avoid grapefruit and grapefruit juice.,Do not suddenly stop taking this medication; abrupt withdrawal may worsen chest pain.,Report symptoms of heart failure such as shortness of breath, swelling of ankles/feet.,May cause dizziness or fatigue; avoid driving until you know how it affects you.,Constipation is common; maintain adequate fluid and fiber intake.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADALAT vs CALAN SR, answered by our medical review team.
ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. CALAN SR is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADALAT and CALAN SR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. The standard adult dose of CALAN SR is: Oral: 180–240 mg once daily; maximum 480 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADALAT and CALAN SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. CALAN SR is classified as Category C. Verapamil (CALAN SR) is classified as FDA Pregnancy Category C. First trimester: Animal studies have shown embryotoxicity and fetotoxicity, but no well-controlled human studies exi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.